Advertisement

CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine

  • Heike Israel
  • Lars Neeb
  • Uwe Reuter
Chronic Daily Headache (S.J. Wang, Section editor)
  • 664 Downloads
Part of the following topical collections:
  1. Topical Collection on Chronic Daily Headache

Abstract

Purpose of Review

CGRP is a key neuropeptide in migraine pathophysiology. The blockade of the CGRP pathway at the side of the CGRP receptor of the CGRP peptide leads to the interruption of trigeminal nerve system-mediated headache syndromes such as migraine. Monoclonal antibodies (mAbs) targeting the CGRP pathway have been developed and are currently under investigation for episodic (EM) and chronic migraine (CM) prevention. Here, we report data from these clinical trials.

Recent Findings

Placebo-controlled, randomized double-blind phase studies of CGRP mAbs in episodic and chronic migraine have shown that the specific blockade of the peptide or the CGRP receptor are both powerful mechanisms to reduce migraine frequency. Along with the reduction of acute migraine-specific medication intake, early onset of efficacy of mAbs has been demonstrated. Most common adverse events are injection sider reactions. Depending on the mAb, the administration mode is a monthly or even less frequently s.c. or I.V. formulation.

Summary

Phase II studies in EM and CM demonstrate that CGRP mAbs are effective anti-migraine preventatives with a beneficial adverse event profile. Further detailed results from larger phase III clinical trials are expected soon.

Keywords

Chronic migraine Episodic migraine CGRP antibody Migraine prevention Antibody safety 

Notes

Compliance with Ethical Standards

Conflict of Interest

UR is a consultant or scientific advisor for Allergan, Amgen, Autonomic Technologies, Eli Lilly, Electrocore, Novartis, and Teva and has received honorarium from these companies for scientific presentations. H Israel and L Neeb have received honoraria from Pharm Allergan, Eli Lilly (LN), Electrocore Novartis (LN), and Autonomic Technologies. UR, LN, and HI are involved as investigators in clinical trials with mAbs from Amgen, Eli Lilly, Novartis, and Teva without personal remuneration.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Mitsikostas DD, Reuter U. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies. Curr Opin Neurol. 2017;30:272–80.CrossRefPubMedGoogle Scholar
  2. 2.
    Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015;79:886–95.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Smillie SJ, Brain SD. Calcitonin gene-related peptide (CGRP) and its role in hypertension. Neuropeptides. 2011;45:93–104.CrossRefPubMedGoogle Scholar
  4. 4.
    Russo AF. CGRP as a neuropeptide in migraine: lessons from mice. Br J Clin Pharmacol. 2015;80:403–14.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478–88.CrossRefPubMedGoogle Scholar
  6. 6.
    Peres MF, Silberstein S, Moreira F, Corchs F, Vieira DS, Abraham N, et al. Patients’ preference for migraine preventive therapy. Headache. 2007;47:540–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Kowacs PA, Piovesan EJ, Tepper SJ. Rejection and acceptance of possible side effects of migraine prophylactic drugs. Headache. 2009;49:1022–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A comparison of the Chronic Migraine Epidemiology and Outcomes (CaMEO) study and American Migraine Prevalence and Prevention (AMPP) study: demographics and headache-related disability. Headache. 2016;56:1280–9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the Second International Burden Of Migraine Study (IBMS-II). Headache. 2013;53:644–55.CrossRefPubMedGoogle Scholar
  10. 10.
    •• Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1091–100. The first phase II trial of a mAbs CGRP receptor antagonist for chronic migraine prevention. CrossRefPubMedGoogle Scholar
  11. 11.
    Cohen JM, Dodick DW, Yang R, Newman LC, Li T, Aycardi E, et al. Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines. Headache. 2017;57:1375–84.CrossRefPubMedGoogle Scholar
  12. 12.
    Silberstein SD, Dodick DW, Lindblad AS, Holroyd K, Harrington M, Mathew NT, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology. 2012;78:976–84.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E, et al. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology. 2016;87:41–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    •• Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425–34. The first phase II trial of a mAbs CGRP receptor antagonist for chronic migraine prevention. CrossRefPubMedGoogle Scholar
  15. 15.
    •• Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–32. The first phase III trial of a mAbs CGRP receptor antagonist for migraine prevention. CrossRefPubMedGoogle Scholar
  16. 16.
    •• Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13:885–92. The first phase II trial of a mAbs CGRP antagonist for migraine prevention. CrossRefPubMedGoogle Scholar
  17. 17.
    Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomized, double blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13:1100–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicenter, randomized, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14:1081–90.CrossRefPubMedGoogle Scholar
  19. 19.
    •• Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:382–9. The first phase II trial of a mAbs CGRP receptor antagonist for migraine prevention. CrossRefPubMedGoogle Scholar
  20. 20.
    Bendtsen L, Mattsson P, Zwart JA, Lipton RB. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia. 2003;23:487–90.CrossRefPubMedGoogle Scholar
  21. 21.
    Reuter U. Anti-CGRP antibodies: a new approach to migraine prevention. Lancet Neurol. 2014;13(9):857–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, et al. Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. Neurology. 2017;89:1237–43.CrossRefPubMedGoogle Scholar
  23. 23.
    •• Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–22. The first phase III trial of a mAbs CGRP antagonist for chronic migraine prevention.CrossRefPubMedGoogle Scholar
  24. 24.
    Vécsei L, Majláth Z, Szok D, Csáti A, Tajti J. Drug safety and tolerability in prophylactic migraine treatment. Expert Opin Drug Saf. 2015;14:667–81.CrossRefPubMedGoogle Scholar
  25. 25.
    Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–80.CrossRefPubMedGoogle Scholar
  26. 26.
    Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. Onabotulinumtoxin for treatment of chronic migraine: results from the double blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.CrossRefPubMedGoogle Scholar
  27. 27.
    Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14.CrossRefPubMedGoogle Scholar
  28. 28.
    Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, et al. Blocking CGRP in migraine patients—a review of pros and cons. J Headache Pain. 2017;18:96.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Chaitman BR, Ho AP, Behm MO, Rowe JF, Palcza JS, Laethem T, et al. A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina. Clin Pharmacol Ther. 2012;91:459–66.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Charité Universitätsmedizin Berlin, Department of NeurologyCharité Headache CenterBerlinGermany

Personalised recommendations